Federico Gulluni

Dr. Federico Gulluni

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center (MBC), Via Nizza 52 - 10124 Torino, Italy
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2014 in Annals of Medicine
Verified
Journal Article
Closed access
PDF file
MMMiriam Martini
Miriam Martini
MSMaria Chiara De Santis
Maria Chiara De Santis
LBLaura Braccini
Laura Braccini
Federico GulluniFederico Gulluni
Federico Gulluni
EHEmilio Hirsch
Emilio Hirsch
Despite development of novel agents targeting oncogenic pathways, matching targeted therapies to the genetic status of individual tumors is proving to be a daunting task for clinicians. To improve the clinical efficacy and to reduce the toxic side effects of treatments, a deep characterization of genetic alterations in different tumors is required. The mutational profile often evidences a gain of function or hyperactivity of phosphoinositide 3-kinases (PI3Ks) in tumors. These enzymes are activated downstream tyrosine kinase receptors (RTKs) and/or G proteins coupled receptors (GPCRs) and, via AKT, are able to induce mammalian target of rapamycin (mTOR) stimulation. Here, we elucidate the impact of class I (p110α, β, γ, and δ) catalytic subunit mutations on AKT-mediated cellular processes that control crucial mechanisms in tumor development. Moreover, the interrelation of PI3K signaling with mTOR, ERK, and RAS pathways will be discussed, exploiting the potential benefits of PI3K signaling inhibitors in clinical use.

3 July 2013 in Nature
Verified
Journal Article
Closed access
PDF file
YPYork Posor
York Posor
MEMarielle Eichhorn-Gruenig
Marielle Eichhorn-Gruenig
DPDmytro Puchkov
Dmytro Puchkov
JSJohannes Schöneberg
Johannes Schöneberg
AUAlexander Ullrich
Alexander Ullrich
VHVolker Haucke
Volker Haucke

14 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HLhuayi li
huayi li
LPLorenzo Prever
Lorenzo Prever
EHEmilio Hirsch
Emilio Hirsch
Federico GulluniFederico Gulluni
Federico Gulluni
Breast cancer is the most frequently diagnosed cancer and the primary cause of cancer death in women worldwide. Although early diagnosis and cancer growth inhibition has significantly improved breast cancer survival rate over the years, there is a current need to develop more effective systemic treatments to prevent metastasis. One of the most commonly altered pathways driving breast cancer cell growth, survival, and motility is the PI3K/AKT/mTOR signaling cascade. In the past 30 years, a great surge of inhibitors targeting these key players has been developed at a rapid pace, leading to effective preclinical studies for cancer therapeutics. However, the central role of PI3K/AKT/mTOR signaling varies among diverse biological processes, suggesting the need for more specific and sophisticated strategies for their use in cancer therapy. In this review, we provide a perspective on the role of the PI3K signaling pathway and the most recently developed PI3K-targeting breast cancer therapies.

1 March 2014 in Developmental Cell
Verified
Journal Article
Open access
IFIrene Franco
Irene Franco
Federico GulluniFederico Gulluni
Federico Gulluni
Carlo C. CampaCarlo C. Campa
Carlo C. Campa
CCCarlotta Costa
Carlotta Costa
JMJean Piero Margaria
Jean Piero Margaria
EHEmilio Hirsch
Emilio Hirsch
Multiple phosphatidylinositol (PtdIns) 3-kinases (PI3Ks) can produce PtdIns3P to control endocytic trafficking, but whether enzyme specialization occurs in defined subcellular locations is unclear. Here, we report that PI3K-C2α is enriched in the pericentriolar recycling endocytic compartment (PRE) at the base of the primary cilium, where it regulates production of a specific pool of PtdIns3P. Loss of PI3K-C2α-derived PtdIns3P leads to mislocalization of PRE markers such as TfR and Rab11, reduces Rab11 activation, and blocks accumulation of Rab8 at the primary cilium. These changes in turn cause defects in primary cilium elongation, Smo ciliary translocation, and Sonic Hedgehog (Shh) signaling and ultimately impair embryonic development. Selective reconstitution of PtdIns3P levels in cells lacking PI3K-C2α rescues Rab11 activation, primary cilium length, and Shh pathway induction. Thus, PI3K-C2α regulates the formation of a PtdIns3P pool at the PRE required for Rab11 and Shh pathway activation.

1 April 2019 in Trends in Cell Biology
Verified
Journal Article
Closed access
Federico GulluniFederico Gulluni
Federico Gulluni
MSMaria Chiara De Santis
Maria Chiara De Santis
JMJean Piero Margaria
Jean Piero Margaria
MMMiriam Martini
Miriam Martini
EHEmilio Hirsch
Emilio Hirsch

1 January 2013 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MMMiriam Martini
Miriam Martini
ECElisa Ciraolo
Elisa Ciraolo
Federico GulluniFederico Gulluni
Federico Gulluni
EHEmilio Hirsch
Emilio Hirsch
The phosphatidylinositol 3-kinase (PI3K) signaling pathway regulates several cellular processes and it’s one of the most frequently deregulated pathway in human tumors. Given its prominent role in cancer, there is great interest in the development of inhibitors able to target several members of PI3K signaling pathway in clinical trials. These drug candidates include PI3K inhibitors, both pan- and isoform-specific inhibitors, AKT, mTOR, and dual PI3K/mTOR inhibitors. As novel compounds progress into clinical trials, it’s becoming urgent to identify and select patient population that most likely benefit from PI3K inhibition. In this review we will discuss individual PIK3CA mutations as predictors of sensitivity and resistance to targeted therapies, leading to use of novel PI3K/mTOR/AKT inhibitors to a more “personalized” treatment.